Immuneering Corporation

NASDAQ•IMRX

執行長: Dr. Benjamin J. Zeskind M.B.A., Ph.D.

板塊: Healthcare

行業: Biotechnology

上市日期: 2021-07-30

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

聯絡資訊

245 Main Street, Second Floor, Cambridge, MA, 02142, United States

617-500-8080

immuneering.com

市值

$206.92M

本益比 (TTM)

-4.5

股息率

52周最高

$10.08

52周最低

$1.10

52周範圍

51%

排名44Top 53.8%

3.7

F-Score

改良版 Piotroski 分析

基於 6 年期基本面

疲弱 • 3.7 / 9 分

評分區間 (0-9)

8-9: 價值優異

6-7: 基本面強勁

4-5: 整體穩健

0-3: 表現疲弱

資料區間: 2020-2025

財務儀表板

Q4 2025 數據

營業收入

$0.00+0.00%

近4季度走勢

每股收益

-$0.18+0.00%

近4季度走勢

自由現金流

-$9.96M+0.00%

近4季度走勢

2025 Annual 財報亮點

核心亮點

Net Loss Decreased Net loss $56.0M for 2025, an 8.2% reduction compared to $61.0M loss reported in 2024.

R&D Spending Reduced Total R&D expenses fell 12.3% to $42.0M in 2025, driven by pausing envometinib program development efforts.

Significant Capital Raised Financing activities provided $226.6M cash, reflecting multiple private placements and public equity offerings during 2025.

Cash Runway Extended Cash reserves $128.6M as of year-end, sufficient to fund operations and development activities into 2029.

關注風險

Late-Stage Clinical Dependency Business substantially dependent on successful atebimetinib development; no products approved for commercial sale currently.

Substantial Capital Needs Requires substantial additional capital to finance operations; failure to raise funds delays or eliminates development programs.

Regulatory Approval Unpredictable Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable regarding outcomes for candidates.

Platform Technology Reliance Business substantially dependent on proprietary platform and information technology systems; failure materially harms operations.

未來展望

Phase 3 Trial Dosing Planned Expect dosing first patient in atebimetinib Phase 3 MAPKeeper 301 trial in mid-2026 for pancreatic cancer indication.

Atebimetinib Data Updates Announce further updated survival data from over 50 first-line pancreatic cancer patients in first half of 2026.

New Combination Trial Dosing Dosing first patient in planned atebimetinib combination trial with Libtayo in NSCLC patients second half 2026.

Envometinib Partnership Focus Paused internal advancement of envometinib; pursuing partnership opportunities and considering other developmental paths.

同行對比

營業收入 (TTM)

ARCT

$74.12M

-46.4%

ASMB

$72.30M

+153.5%

CDXS

$70.39M

+18.6%

毛利率 (最新季度)

PYXS

103.9%

+0.0pp

ENTA

100.0%

+0.0pp

ASMB

99.9%

+0.0pp

關鍵指標

股票代碼	市值	本益比 (TTM)	股東權益報酬率 (TTM)	負債率
SLS	$678.02M	-27.1	-63.1%	1.3%
TRDA	$531.77M	-4.0	-39.8%	13.5%
ASMB	$463.83M	-53.5	-5.6%	1.0%

長期趨勢

近4季度

營業收入

淨利

營運現金流

4季度營業收入複合增長率

N/M

營業收入波動較大

4季度淨利複合增長率

N/M

盈利狀態轉變

現金流穩定性

現金流需要關注

深度研究

下次財報:2026年5月4日

每股收益:-$0.30

營業收入:-

財務數據

電話會議

財務報告

新聞

損益表

資產負債表

現金流量表

財務比率

變化率

損益表	過去12個月

無資料